First‑Line Inotropic and Vasopressor Therapy in Cardiogenic Shock
Initial Hemodynamic Targets
- Aim for a mean arterial pressure ≥ 65 mmHg and a systolic blood pressure > 90 mmHg in all patients with cardiogenic shock. 1
Fluid Management
- Perform a 250 mL fluid challenge over 10 minutes only when there are no clinical signs of fluid overload (e.g., no pulmonary congestion, normal jugular venous pressure). 2
Inotropic Therapy Selection
Normotensive or Mildly Hypotensive Patients (SBP 70‑100 mmHg)
- Dobutamine 2‑20 µg·kg⁻¹·min⁻¹ is the recommended first‑line inotrope. [1][3]
- Titrate dobutamine to improve cardiac output and organ‑perfusion markers such as urine output, lactate clearance, and mental status. 1
Hypotensive Patients with Tachycardia (SBP < 90 mmHg)
- Add norepinephrine starting at 0.03 µg·min⁻¹ and titrate up to 30 µg·min⁻¹ as the primary vasopressor when systolic pressure remains <90 mmHg despite inotropic support. [1][3]2
Hypotensive Patients with Bradycardia
- Dopamine 5‑15 µg·kg⁻¹·min⁻¹ may be used instead of dobutamine. [1][3]
- Be aware that dopamine increases the risk of tachyarrhythmias and should be used cautiously. 4
Alternative and Adjunctive Agents
- Levosimendan can be considered when patients are on chronic β‑blocker therapy and dobutamine is likely ineffective. 2
- Phosphodiesterase‑III inhibitors (milrinone, enoximone) are second‑line options but should be avoided in patients with coronary artery disease because of a potential increase in medium‑term mortality. 2
Mechanical Circulatory Support
- Consider intra‑aortic balloon pump (IABP) as a bridge to urgent revascularization when pharmacologic therapy does not rapidly reverse shock. [5][3]
- Escalate to advanced mechanical circulatory support if:
Early Revascularization
- Perform early revascularization (PCI or CABG) within 18 hours of shock onset; this strategy saves approximately 13 lives per 100 treated patients. [5][3]
- Indicated for patients < 75 years who develop shock within 36 hours of myocardial infarction, and may also benefit selected patients ≥ 75 years with good prior functional status. [5][3]
Monitoring and Perfusion Targets
- Urine output > 0.5 mL·kg⁻¹·hr⁻¹. 1
- Lactate clearance – serially decreasing lactate concentrations. 1
- Neurological status – improvement in mental alertness. 1
- Cardiac index ≥ 2.5 L·min⁻¹·m⁻². 3
- Pulmonary artery catheterization may be employed to guide therapy. [5][3]
Special Situations
- In afterload‑dependent states (e.g., severe aortic or mitral stenosis), use phenylephrine or vasopressin rather than inotropes that increase contractility; avoid dobutamine. 1
- For right‑ventricular infarction, assess with right‑sided ECG leads (V4R) and echocardiography; maintain adequate preload and avoid excessive diuresis. 3
Contra‑indicated Therapies
- Do not use β‑blockers or calcium‑channel blockers in acute cardiogenic shock with pulmonary congestion or low‑output state. [5][3]
- Avoid simultaneous administration of hypotensive agents (nitrates, diuretics, ACE inhibitors) that can precipitate iatrogenic shock. [5][3]
- Epinephrine should be reserved for cardiac arrest; it is not recommended as an inotrope or vasopressor in cardiogenic shock. 2
- Phenylephrine is limited to salvage therapy when other agents fail. 4
- Do not postpone definitive revascularization for prolonged medical optimization; pharmacologic support serves only as a bridge. [5][3]
Dosing Summary
| Agent | Starting Dose | Maximum Dose | Primary Indication |
|---|---|---|---|
| Dobutamine | 2 µg·kg⁻¹·min⁻¹ | 20 µg·kg⁻¹·min⁻¹ | First‑line inotrope [1][3] |
| Norepinephrine | 0.03 µg·min⁻¹ | 30 µg·min⁻¹ | Persistent hypotension [3] |
| Dopamine | 5 µg·kg⁻¹·min⁻¹ | 15 µg·kg⁻¹·min⁻¹ | Bradycardia with hypotension [1][3] |
| Vasopressin | 0.01 U·min⁻¹ | 0.03 U·min⁻¹ | Afterload‑dependent states [1] |
Management of Refractory Cardiogenic Shock
Vasopressor and Inotrope Strategy
Epinephrine is contraindicated as a primary vasopressor/inotrope in cardiogenic shock because it induces visceral hypoperfusion, hyperlactatemia, and worsens organ function and survival; it should be stopped immediately. – European Society of Cardiology (ESC) recommendation 6
Dopamine should be discontinued or markedly reduced in cardiogenic shock due to a high arrhythmia risk (≈ 25 %), lack of renal‑protective effect, and inferior hemodynamic efficacy compared with norepinephrine. – ESC recommendation [7][8]
Adopt a two‑drug regimen:
- Norepinephrine (0.03–30 µg/min) as the primary vasopressor to keep mean arterial pressure ≥ 65 mmHg and systolic blood pressure > 90 mmHg. – ESC recommendation [7][8]
- Dobutamine (2.5–20 µg/kg/min) as the primary inotrope to augment cardiac output. – ESC recommendation [7][8]
If the patient has significant tachycardia (heart rate > 100–110 bpm), replace dobutamine with milrinone (0.375–0.75 µg/kg/min, no bolus in hypotension); note that milrinone carries an increased mortality risk in patients with coronary artery disease. – ESC recommendation [7][8]
Mechanical Circulatory Support
- Patients who have failed optimized two‑drug therapy and remain hypotensive (systolic BP ≤ 90 mmHg) or show signs of organ hypoperfusion (oliguria, rising lactate, altered mental status) require escalation to advanced mechanical circulatory support (Impella, veno‑arterial ECMO, or TandemHeart) as a bridge to definitive therapy. – ESC guideline 9
Early Revascularization
- Early revascularization performed within 18 hours of shock onset saves approximately 13 lives per 100 patients and is the only intervention proven to reduce mortality in ischemic cardiogenic shock. – ESC guideline 9
Fluid Management Pitfalls
- Do not use vasopressors to compensate for inadequate volume resuscitation; instead, give a 250 mL fluid challenge over 10 minutes when there are no signs of fluid overload (e.g., no pulmonary congestion, normal jugular venous pressure). – ESC guidance [6][9]